Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr:103:29-38.
doi: 10.1016/j.brainresbull.2013.12.006. Epub 2013 Dec 12.

Abnormal kalirin signaling in neuropsychiatric disorders

Affiliations
Review

Abnormal kalirin signaling in neuropsychiatric disorders

Christine Remmers et al. Brain Res Bull. 2014 Apr.

Abstract

Changes in dendritic spines structure and function play a critical role in a number of physiological processes, including synaptic transmission and plasticity, and are intimately linked to cognitive function. Alterations in dendritic spine morphogenesis occur in a number of neuropsychiatric disorders and likely underlie the cognitive and behavioral changes associated with these disorders. The neuronal guanine nucleotide exchange factor (GEF) kalirin is emerging as a key regulator of structural and functional plasticity at dendritic spines. Moreover, a series of recent studies have genetically and functionally linked kalirin signaling to several disorders, including schizophrenia and Alzheimer's disease. Kalirin signaling may thus represent a disease mechanism and provide a novel therapeutic target.

Keywords: Alzheimer's disease; Genetic; Glutamatergic; Mental disorder; Postmortem; Schizophrenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Kalirin-7 is localized to dendritic spines and modulates dendritic spine morphogenesis
(A) This schematic of kalirin isoforms and domains shows the N-terminal Sec14p domain, followed by nine spectrin-like repeats common to all kalirin isoforms. The Dbl homology (DH) and pleckstrin homology (PH) domains confer kalirin’s GEF activity. The first GEF domain activates Rac1 and is present in kalirin-7, -9 and -12. Kalirin-7 also has a unique C-terminal PDZ-binding domain. Kalirin-9 and -12 have an SH3 domain and a second GEF domain that activates RhoA. Kalirin-12 has C-terminal fibronectin III-like and immunoglobulin-like domains as well as a kinase domain. (B) Kalirin-7 is localized to dendritic spines of cortical pyramidal neurons.
Figure 2
Figure 2. Kalirin-7 interacts with schizophrenia-associated proteins
Under non-pathological conditions, kalirin interacts with a number of schizophrenia-associated proteins. Activation of postsynaptic NMDARs leads to increased trafficking of AMPARs to the post-synaptic density. NMDAR activation also leads to dissociation of the PDS-95/DISC1/kalirin-7 complex, allowing kalirin-7 to activate Rac1. Post-synaptic erbB4 receptors are activated by NRG1 and modulate dendritic spines in a kalirin-dependent manner. 5-HT2A receptor activation also regulates spine density through kalirin. Kalirin-7 activates Rac1 by exchanging GDP for GTP. Rac1 in turn activates PAK, which then initiates actin remodeling. Kalirin-7, DISC1, erbB4, NRG1, 5-HT2A, PAK2 and PAK3 have been genetically associated with schizophrenia.
Figure 3
Figure 3. Kalirin-7 interacts with Alzheimer’s disease-associated proteins
Amyloid β oligomers bind to dendritic spines in AD, leading to decreased surface expression of NMDARs and EphB2 receptors. This likely causes decreased kalirin/Rac/PAK signaling, leading to synapse loss and cognitive impairment. Aβ oligomers, kalirin-7, and PAK have been associated with AD.
Figure 4
Figure 4. Reductions in kalirin isoforms relative to control in Braak stages 3–5
(A) and Braak stage 6 (B) subjects. (C) Aβ ratio by Braak stage. AD−P: AD without psychosis; AD+P: AD with psychosis; * p < 0.05, ** p<0.001.

Similar articles

Cited by

References

    1. Alvarez VA, Sabatini BL. Anatomical and physiological plasticity of dendritic spines. Annu Rev Neurosci. 2007;30:79–97. - PubMed
    1. Amano M, Kaneko T, Maeda A, Nakayama M, Ito M, Yamauchi T, Goto H, Fukata Y, Oshiro N, Shinohara A, Iwamatsu A, Kaibuchi K. Identification of Tau and MAP2 as novel substrates of Rho-kinase and myosin phosphatase. J Neurochem. 2003;87:780–790. - PubMed
    1. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 2009;118:167–179. - PubMed
    1. Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci. 2005;6:376–387. - PubMed
    1. Baloyannis SJ, Costa V, Mauroudis I, Psaroulis D, Manolides SL, Manolides LS. Dendritic and spinal pathology in the acoustic cortex in Alzheimer's disease: morphological and morphometric estimation by Golgi technique and electron microscopy. Acta Otolaryngol. 2007;127:351–354. - PubMed

Publication types

Substances